Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company ...

Biotech IPO activity in the US has spiked for the second time this year, following an initial boost in Q1 2024. Largely ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting ...

Eli Lilly 's (NYSE: LLY) stock is up by more than 736% over the last five years, largely thanks to its best-selling medicines ...

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

A new report identifies six Massachusetts startup "unicorns" as life science companies most likely to hold initial public ...

The US IPO market is seeing renewed momentum as the 2024 presidential election approaches, with investors and analysts eyeing ...

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug ...